Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00755469 · ClinicalTrials.gov registry record · NA
Post-conditioning to Reduce Infarct Size
A NA study, sponsored by Minneapolis Heart Institute Foundation.
- Completed
- Registry status
- NA
- Development phase
- 43
- Enrollment target
NCT00755469: Completed NA study, sponsored by Minneapolis Heart Institute Foundation.
NCT00755469 is a NA study that has completed, run by Minneapolis Heart Institute Foundation. The registered enrollment target is 43 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00755469, a NA study, has completed, sponsored by Minneapolis Heart Institute Foundation.
- COMPLETED
- Registry status
- NA
- Development phase
- 43 participants
- Enrollment target
Study Summary
When angioplasty (PTCA) and stenting of the blood vessels of the heart is the treatment for a Heart Attack, there is damage to the heart muscle that is caused by the sudden opening of the blood vessels. This is called "reperfusion injury". The cell death is due to inflammation and the generation of free radicals. The primary objective of this study is to determine if post-conditioning(four brief (30 second) PTCA balloon inflations) reduces damage to the heart muscle. This will be measured by heart enzyme tests-CK measurements- and by cardiac MRI.
Interventions
- PROCEDURE Post-conditioning
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2008-09 |
| Est. Completion | 2010-08 |
| Phase | NA |
What the finished NCT00755469 record still lists
NCT00755469 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Post-conditioning is the first listed.
NCT00755469 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00755469 about?
NCT00755469 is a clinical study titled "Post-conditioning to Reduce Infarct Size". When angioplasty (PTCA) and stenting of the blood vessels of the heart is the treatment for a Heart Attack, there is damage to the heart muscle that is caused by the sudden opening of the blood vessels. This is called "reperfusion injury". The cell death is due to inflammation and the generation of ...
What is the current status of trial NCT00755469?
This trial is currently completed. It is a NA study. The enrollment target is 43 participants. The study started on 2008-09. Estimated completion is 2010-08.
What interventions are being tested in trial NCT00755469?
The interventions under investigation include: Post-conditioning (PROCEDURE).
Who is sponsoring clinical trial NCT00755469?
This trial is sponsored by Minneapolis Heart Institute Foundation, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00755469's enrollment target sits among peer trials
43 1435th of 2000 higher than 565 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia